The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia

Maria Rosa Ciardi, Maria Antonella Zingaropoli, Patrizia Pasculli, Valentina Perri, Matteo Tartaglia, Serena Valeri, Gianluca Russo, Antonella Conte, Claudio Maria Mastroianni

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)

Abstract

A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia (infection). At the infection time point, no differences in the percentages of immune activation and immunesenescence of CD4+ and CD8+ T-cells were observed compared to the pre-infection time point. Our evaluation seems to confirm that teriflunomide controls T-cells immune activation and immunosenescence suggesting that teriflunomide should not be discontinued in MS patients with an active COVID-19 pneumonia.

Original languageEnglish
Pages (from-to)577323
JournalJournal of Neuroimmunology
Volume346
DOIs
Publication statusE-pub ahead of print - Jul 15 2020

Fingerprint Dive into the research topics of 'The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia'. Together they form a unique fingerprint.

Cite this